China Traditional Chinese Medicine Holdings Co Ltd (CHIZF)
OTHER OTC:CHIZF
CHIZF Stock Chart & Stats
$0.27
$0.00(0.00%)
At close: 4:00 PM EDT
$0.27
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.22 - $0.35
Previous CloseN/A
Volume90.00K
Average Volume (3M)6.00
Market Cap
$951.22M
Enterprise Value$5.23B
Total Cash (Recent Filing)$5.16B
Total Debt (Recent Filing)$2.49B
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.03%
Share Statistics
EPS (TTM)-0.07
Shares Outstanding5,035,802,000
10 Day Avg. Volume0
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.46
Price to Sales (P/S)0.64
P/FCF Ratio4.83
Enterprise Value/Market Cap5.50
Enterprise Value/Revenue0.35
Enterprise Value/Gross Profit0.74
Enterprise Value/Ebitda3.69
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)$1.83B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet; Falling LeverageA conservative balance sheet with falling debt and substantial equity provides durable financial flexibility, lowers refinancing risk, and supports continued operations during earnings cycles. This structural strength helps absorb shocks and gives management optionality for investment or restructuring over months.
Strong Recent Operating And Free Cash FlowConsistent operating and free cash flow in 2024–2025 shows the business still converts sales into cash even amid earnings weakness. Durable cash generation supports working capital, capex and shareholder distributions, and can fund turnarounds without immediate reliance on external financing.
Underlying Healthy Gross ProfitA healthy gross profit base indicates the core product economics remain viable, giving room to restore margins if operating costs are controlled. This structural profitability at the gross level supports recovery potential and long-term competitiveness in specialty/generic drugs.
Bears Say
Profitability Slid To A Net Loss In 2025A shift from multi-year profitability to a net loss in 2025 is a durable red flag: it reduces reinvestment capacity, strains returns on equity, and undermines the company's ability to compound shareholder value absent a credible recovery in margins or revenue.
Uneven And Contracting Revenue TrendsRepeated revenue declines and volatility suggest structural demand or pricing pressure and weaken predictability of future cash flows. Persistent top-line weakness hampers operating leverage, makes cost recovery harder, and raises execution risk for any margin restoration plan.
Volatile Longer-term Cash Flows; FCF Growth Declined In 2025While recent cash generation is positive, historical FCF volatility and a sharp slowdown in FCF growth in 2025 undermine confidence in durability. Inconsistent cash flows constrain strategic investments and make sustaining dividends or funding turnarounds without external capital more difficult.
China Traditional Chinese Medicine Holdings Co News
CHIZF FAQ
What was China Traditional Chinese Medicine Holdings Co Ltd’s price range in the past 12 months?
China Traditional Chinese Medicine Holdings Co Ltd lowest stock price was $0.22 and its highest was $0.34 in the past 12 months.
What is China Traditional Chinese Medicine Holdings Co Ltd’s market cap?
China Traditional Chinese Medicine Holdings Co Ltd’s market cap is $951.22M.
When is China Traditional Chinese Medicine Holdings Co Ltd’s upcoming earnings report date?
China Traditional Chinese Medicine Holdings Co Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 73 days.
How were China Traditional Chinese Medicine Holdings Co Ltd’s earnings last quarter?
China Traditional Chinese Medicine Holdings Co Ltd released its earnings results on Mar 20, 2026. The company reported -$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.007.
Is China Traditional Chinese Medicine Holdings Co Ltd overvalued?
According to Wall Street analysts China Traditional Chinese Medicine Holdings Co Ltd’s price is currently Overvalued.
Does China Traditional Chinese Medicine Holdings Co Ltd pay dividends?
China Traditional Chinese Medicine Holdings Co Ltd pays a Monthly dividend of $0.011 which represents an annual dividend yield of 4.03%. See more information on China Traditional Chinese Medicine Holdings Co Ltd dividends here
What is China Traditional Chinese Medicine Holdings Co Ltd’s EPS estimate?
China Traditional Chinese Medicine Holdings Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Traditional Chinese Medicine Holdings Co Ltd have?
China Traditional Chinese Medicine Holdings Co Ltd has 5,035,802,000 shares outstanding.
What happened to China Traditional Chinese Medicine Holdings Co Ltd’s price movement after its last earnings report?
China Traditional Chinese Medicine Holdings Co Ltd reported an EPS of -$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of China Traditional Chinese Medicine Holdings Co Ltd?
Currently, no hedge funds are holding shares in CHIZF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
China Traditional Chinese Medicine Holdings Co Ltd
China Traditional Chinese Medicine Holdings Co. Limited functions as an investment holding company, primarily focusing on the research, development, and sale of traditional Chinese medicine and other pharmaceutical goods across the People's Republic of China. The company's product range includes medicinal granules, finished pharmaceutical preparations, pre-portioned decoction materials, and various healthcare products. Furthermore, its operations extend to the cultivation and management of Chinese medicinal herbs, the manufacturing of traditional Chinese medicines, and the trading of pharmaceutical products. It also delivers marketing, advertising, and consulting services related to TCM, and operates retail outlets for pharmaceuticals and decoction products. Property leasing services represent another facet of its business. The company distributes its products to healthcare facilities and retail pharmacies. Established in 1573 and headquartered in Wan Chai, Hong Kong, the firm was formerly known as China Traditional Chinese Medicine Co. Limited before adopting its current name in July 2016.
China Traditional Chinese Medicine Holdings Co (CHIZF) Earnings & Revenues
Technical Analysis
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Wai Yuen Tong Medicine Holdings Limited
―
Grand Pharmaceutical Group Limited
―
Golden Throat Holdings Group Co Ltd
―
Shandong Xinhua Pharmaceutical Company Limited Class H
―
Ownership Overview
―
Insiders
3.11% Mutual Funds
0.37% Other Institutional Investors
93.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---